Rhythm Pharmaceuticals Inc（RYTM）資訊與事件RYTMRhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals' IMCIVREE Approved by Health Canada for Weight Management

Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity. IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome, or genetically confirmed biallelic pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance.

Rhythm Pharmaceuticals Releases Preliminary Data on Prader-Willi Syndrome Trial

Rhythm Pharmaceuticals announced preliminary data from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome delivered during the Endocrine Society's Annual Meeting in Chicago. Key highlights include: Patients with PWS treated with setmelanotide therapy achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures; Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS